GLP-1 / Weight Loss

AOD-9604 vs Tirzepatide: Research Peptide vs FDA-Approved GLP-1

Verdict Summary

Tirzepatide has robust clinical trial data and FDA approval. AOD-9604 has limited human data and failed its FDA approval process. For clinically validated fat loss, tirzepatide is the evidence-based choice.

Medical Disclaimer: This comparison is for educational purposes only. Consult a healthcare provider before starting any peptide protocol. Full disclaimer →

At a Glance

DimensionAOD-9604Tirzepatide
FDA StatusNot approved (failed Phase 3)Approved (2022)
Clinical EvidenceLimited human dataExtensive (SURMOUNT trials)
MechanismHGH fragment, lipolysis stimulationGIP + GLP-1 dual agonist
Avg. Weight LossModest in trials~20-22%

AOD-9604 Deep Dive

AOD-9604 is a fragment of human growth hormone (hGH176-191) that was studied for fat loss. Despite promising preclinical data, it failed to demonstrate significant weight loss in Phase 3 trials and did not receive FDA approval.

Tirzepatide Deep Dive

Tirzepatide has demonstrated ~20-22% average weight loss in the SURMOUNT trials, making it one of the most effective weight loss medications ever studied. It has FDA approval for both diabetes (Mounjaro) and obesity (Zepbound).

How to Choose

Choose AOD-9604 if…

  • You are a researcher interested in GH-fragment mechanisms
  • You want a research compound with a different mechanism
  • You are exploring alternatives to GLP-1 agonists

Choose Tirzepatide if…

  • Clinically validated, significant weight loss is the goal
  • FDA-approved treatment is required
  • You want the most evidence-based option

Still Unsure?

Get a personalized recommendation

Take the 5-minute PeptidePilot quiz. Our algorithm evaluates your goals, body, and lifestyle to recommend the right peptide for you — vendor-neutral.

Frequently Asked Questions

More Comparisons